What is MOTS-c? The research and its FDA status

Quick answer MOTS-c is a small peptide encoded in the DNA inside mitochondria, the parts of a cell that handle its energy metabolism, and FDA's reviewers found no published study of it given to people. In July 2026 an FDA advisory committee reviewed it, and news reports say the committee recommended adding it to the list of ingredients pharmacies may compound, even though FDA's own staff had proposed against it. Today nothing has changed: MOTS-c is not FDA-approved and not on that list, so licensed pharmacies can't compound it. The next real signal would be a proposed rule from FDA, and there was none as of October 2026.

What is MOTS-c?

Most of your genes sit in the cell's nucleus. Mitochondria, the structures that run much of a cell's energy metabolism, carry a small set of genes of their own. In 2015, researchers reported that a short stretch of that mitochondrial DNA encodes a peptide of 16 amino acids, which they named MOTS-c (Lee and colleagues, 2015). FDA's briefing document for the July 2026 meeting describes it the same way. The MOTS-c discussed online is a lab-made (synthetic) version.

MOTS-c has become popular online on the strength of early mouse research. Early-stage research tells scientists where to look next. It doesn't tell anyone what a product does in people.

What the research measured

The research is early, and almost all of it is in mice and cells.

• FDA's review staff found no published studies of MOTS-c given to people, by any route.
• The 2015 paper that named it, and a 2021 follow-up, tested it in mice and cells; the 2021 paper also measured the body's own MOTS-c in ten men, without giving anyone MOTS-c.
• FDA's staff noted that the studies didn't test a range of amounts, and that the molecular target through which it acts is unknown.

The detail, study by study:

The 2015 paper. Researchers at the University of Southern California and UCLA, with the National Institute on Aging, tested MOTS-c in cells and in mice. Male mice on a high-fat diet were given daily injections into the abdominal cavity for eight weeks, ten mice per group. Treated mice gained less weight than untreated mice on the same diet; in mice on a normal diet, body weight didn't differ. The paper also reported that MOTS-c switched on AMPK, an enzyme involved in energy metabolism, in cells. Some authors disclosed consulting roles with a biotechnology company, CohBar, Inc. (Lee and colleagues, 2015).

The 2021 paper. The same group, with collaborators in New Zealand and Canada, tested MOTS-c in mice aged 2, 12 and 22 months and reported differences in physical capacity on treadmill and other tests. In ten healthy young men who cycled on a stationary bike in New Zealand, it measured the body's own MOTS-c in tissue and blood, and found higher levels after exercise. Nobody in that part of the study was given MOTS-c. The paper also reported a trend toward longer life in mice treated late in life and said larger groups would be needed to confirm it; FDA's briefing describes that result more strongly than the paper does (Reynolds and colleagues, 2021).

What FDA summarized. The other published work is in rodents and cells and covers sugar and fat handling, bone and blood vessels. One test-tube study found MOTS-c broken down quickly in human blood, which raises the question of whether an injected product would reach active levels in people. Results in mice often don't carry over to people.

Full citations are in the Sources list below.

Where MOTS-c stands with FDA

MOTS-c is not an FDA-approved drug and is not on FDA's 503A bulks list, so licensed pharmacies can't compound it; FDA removed it from its interim Category 2 on April 22, 2026 after the nominators withdrew their nominations, which FDA says is not a determination about the substance (how the categories work). In July 2026 FDA's reviewers proposed against adding it to the list, news reports (STAT, July 24, 2026) say the advisory committee voted to recommend adding it anyway, and only a final rule after notice-and-comment rulemaking would change that, with no proposed rule published as of October 6, 2026 (the vote and the rulemaking path).

Before you trust anyone offering MOTS-c

Fair questions to put to any clinic or seller:

• What is the legal basis? As of October 2026 it is not on the 503A bulks list.
• Which state-licensed pharmacy compounds it? You should be able to check its license with the state board of pharmacy.
• Who made the ingredient, and is there a certificate of analysis? Free base and acetate salt are different ingredients.
• Is a licensed provider in your state reviewing your health history, and can they say no?
• Is the claim based on people or mice?
• Where do reactions get reported? FDA takes reports through MedWatch.

Is this right for me?

Not today. No licensed pharmacy can compound MOTS-c, so a provider can't prescribe it through a lawful pharmacy, whatever your goals or health history. Only a final FDA rule changes that.

Your real options right now:

• Wait on the news, not a product. The sign-up at the end of this page covers availability, nothing else.
• See your own doctor about the goal behind your interest, whether that's weight, metabolism or exercise. They can go through approved options.
• Avoid "research use only" products. In August 2026, FDA wrote to online peptide sellers that the label didn't stop their products from being treated as drugs meant for people.

If FDA's rules ever change, an independent licensed provider in your state would still review your history and decide. The answer may be no.

How it works

1. Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
2. Hear from us only if it becomes available through a licensed provider. We write about availability and nothing else, and you can unsubscribe anytime.
3. A licensed provider still decides. Being on the list is not a reservation or a prescription. If FDA's rules change, a provider licensed in your state reviews your health history first and can decline.

FAQ

Is MOTS-c FDA-approved? No. No FDA-approved product contains it.

Is MOTS-c legal to compound now? It is not on the 503A bulks list, so licensed pharmacies can't compound it. Questions about a particular seller are for a lawyer.

Did the FDA advisory committee approve MOTS-c? No. An advisory committee can only recommend, and FDA has to finish rulemaking first. Being on the bulks list would not make it an approved drug.

Has MOTS-c been tested in people? FDA's review found no published studies of MOTS-c given to people. A 2021 study measured the body's own MOTS-c after exercise in ten healthy young men.

When could it become available? No one can give a date. A proposed rule in the Federal Register would be the first real signal.

What this means for you

As of October 2026, licensed pharmacies can't legally compound MOTS-c for patients: it isn't on FDA's 503A bulks list, and only FDA rulemaking changes that. If FDA lists it one day, the legal route would be a prescription from a licensed provider in your state, filled by a licensed pharmacy; compounded medications are not FDA-approved. Until then, products sold online as "research use only" aren't made for people.

The July 2026 FDA peptide vote, explained covers all seven peptides the committee reviewed and what has to happen next.

Safety information

FDA's safety page (content current as of April 22, 2026) says, word for word: "Compounded drugs containing MOTs-C may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration. FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans."

• Missing safety studies. FDA's briefing found no studies of single or repeated exposure, genetic damage, reproduction or cancer.
• Immune reactions. Injected peptides can clump together or carry manufacturing impurities, and FDA says it can't rule out immune reactions to them.
• Quality. FDA found MOTS-c poorly characterized for compounding and found no test data on impurities or clumping.
• Adverse-event reports. FDA's database held none through March 2025. Pharmacies compounding under 503A generally don't report to FDA, so a lack of reports doesn't mean a lack of problems.
• "Research use only" products. FDA's briefing says MOTS-c appears to be marketed on websites as an injectable, alone and mixed with other substances. FDA has said in writing that a "research use only" label doesn't change its view when a seller's website shows the product is meant for people. Products sold online as "research use only" are a different, unregulated market that Everlon does not participate in and that carries additional dangers. What the label means.
• Had a reaction? Tell a doctor and report it to FDA's MedWatch.

If this is a medical emergency, call 911.

Sources

• Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. PMID: 25738459. PubMed, accessed 2026-10-06
• Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. PMID: 33473109. PubMed, accessed 2026-10-06
• FDA. FDA Briefing Document: MOTS-c-related bulk drug substances. Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov, accessed 2026-10-06
• FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov, accessed 2026-10-06
• FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov, accessed 2026-10-06
• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (interim categories list). Updated May 14, 2026. fda.gov, accessed 2026-10-06
• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (interim categories list), version updated April 22, 2026, archived copy; MOTS-c removed from Category 2 because its nomination was withdrawn. web.archive.org, accessed 2026-10-06
• FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov, accessed 2026-10-06
• FDA. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act: Guidance for Industry. January 2025. fda.gov, accessed 2026-10-06
• FDA. Pharmacy Compounding Advisory Committee; Notice of Meeting; Request for Comments. Federal Register. 2026;91:20465. FR Doc. 2026-07361, Docket FDA-2025-N-6895. April 16, 2026. federalregister.gov, accessed 2026-10-06
• FDA. Warning Letters (index; the five CDER letters to online peptide sellers dated August 24, 2026, posted September 1, 2026). fda.gov, accessed 2026-10-06
• STAT News. FDA advisory panel rejects compounding of one peptide, backs another. July 24, 2026 (news report of the committee votes). statnews.com, accessed 2026-10-06
• 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov, accessed 2026-10-06
• 21 U.S.C. 353a, Pharmacy compounding. Cornell Legal Information Institute. law.cornell.edu, accessed 2026-10-06